(MENAFN- GlobeNewsWire - Nasdaq) The global CAR T-Cell therapy market for non-Hodgkin's lymphoma is rapidly expanding, driven by innovative clinical advancements and the pressing need for effective treatments in relapsed cases. Affecting over 500,000 individuals annually, non-Hodgkin's lymphoma, especially aggressive types like diffuse large B-cell lymphoma, represents a significant health burden. CAR T-Cell therapy is emerging as a potential cure, achieving over 50% complete response rates in clinical trials. The market's growth is further supported by FDA-approved therapies such as Yescarta, Kymriah, and Breyanzi, and a focus on next-generation CAR T innovations, including dual-targeted and allogeneic platforms.

Dublin, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets's offering.
The global CAR T-Cell therapy market for non-hodgkin's lymphoma (NHL) is witnessing a robust expansion, driven by a convergence of clinical innovation, rising disease prevalence, and the unmet need for durable treatments in relapsed or refractory cases.

Non-hodgkin's lymphoma, a heterogeneous group of lymphoid malignancies, affects over 500,000 individuals globally each year, with aggressive subtypes such as diffuse large b-cell lymphoma (DLBCL) representing a significant burden. The emergence of chimeric antigen receptor (CAR) T-Cell Therapy as a transformative modality is reshaping the therapeutic landscape, offering a potential cure for patients unresponsive to conventional treatments such as chemotherapy or stem cell transplantation.
Growth in the CAR T-cell therapy market is largely propelled by the remarkable efficacy outcomes demonstrated in clinical trials, with some therapies reporting complete response rates exceeding 50% in difficult-to-treat populations. This has catalyzed regulatory approvals across major markets for therapies such as yescarta, kymriah, and breyanzi. As the clinical success translates into real-world data, the focus is expanding from third-line treatment to earlier lines of therapy, supported by recent trial readouts and updated treatment guidelines.
The CAR T-cell therapy market is evolving rapidly as healthcare providers and biopharmaceutical companies prioritize the development of next-generation therapies, aiming to improve safety, scalability, and long-term outcomes. Key areas of focus include dual-targeted CARs, armored CARs with cytokine modulation, and allogeneic CAR T-cell platforms that address the logistical challenges of autologous manufacturing. These advancements are complemented by ongoing investments in decentralized manufacturing technologies and artificial intelligence to streamline the production cycle and reduce vein-to-vein times.
Healthcare infrastructure improvements and the expansion of certified CAR T-cell treatment centers particularly across the U.S., Europe, and China - are enhancing patient access to these life-extending therapies. Favourable reimbursement frameworks and risk-sharing models introduced in high-income countries have played a pivotal role in mitigating the financial burden on hospitals and patients. Moreover, precision medicine initiatives and biomarker-driven patient selection protocols are enabling better targeting, improving response rates, and minimizing adverse effects.
Innovation in digital health integration including mobile apps for post-treatment monitoring, AI tools for toxicity prediction, and remote consultation platforms is further strengthening treatment adherence and patient safety. The market is also seeing increasing alignment with value-based care models, where outcomes such as durable remission and reduced hospitalization rates justify premium pricing and facilitate long-term payer adoption.
Despite its strong growth outlook, the CAR T-cell therapy market for NHL is not without challenges. High treatment costs often exceeding $400,000 per infusion remain a significant barrier in low- and middle-income countries, and even in developed regions without universal coverage. The complexity of manufacturing, coupled with limited access to qualified treatment centers, constrains scalability and delays treatment for aggressive lymphoma subtypes. Additionally, cytokine release syndrome (CRS) and neurotoxicity, though increasingly manageable, necessitate specialized care and remain risks that can limit broader adoption. Regulatory bottlenecks and long development timelines for newer CAR T platforms can also delay market entry and innovation cycles.
The competitive landscape is characterized by the active engagement of global pharmaceutical giants, emerging biotech firms, and academic research consortia. Strategic collaborations, mergers, and licensing agreements are prevalent as stakeholders seek to bolster pipelines and gain competitive advantage in novel CAR constructs, allogeneic platforms, and tumor-specific targeting. R&D investments in synthetic biology, gene editing and immune modulation technologies are likely to define the next wave of disruption in this space.
Looking ahead, the CAR T-cell therapy market for non-hodgkin's lymphoma is positioned for sustained growth, bolstered by expanding indications, improving patient access, and a deep innovation pipeline.

As the field continues to converge with precision oncology, genomics, and digital therapeutics, CAR T-cell therapy is set to become a cornerstone in the long-term management of hematologic malignancies. With ongoing emphasis on patient-centric care, scalable delivery models, and broader global access, the market is well-positioned to significantly elevate survival outcomes and quality of life for patients battling this aggressive cancer.
Key Topics Covered:
1. Global CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market: Industry Analysis
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
2. Global CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market (by Indication)
2.1 Diffuse Large B-Cell Lymphoma
2.2 Follicular Lymphoma
2.3 Mantle Cell Lymphoma
2.4 Others
3. Global CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market (by Therapy)
3.1 Autologous CAR T-Cell Therapy
3.2 Allogeneic CAR T-Cell Therapy
4. Global CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market (by Region)
4.1 North America
4.2 Europe
4.3 Asia-Pacific
4.4 Rest-of-the-World
5. Competitive Landscape and Company Profiles
5.1 Competitive Landscape
5.1.1 Mergers and Acquisitions
5.1.2 Partnership, Alliances and Business Expansion
5.1.3 New Offerings
5.1.4 Regulatory Activities
5.1.5 Funding Activities
5.2 Company Profiles

• Allogene Therapeutics
• Autolus Therapeutics
• Bristol Myers Squibb
• Crispr Therapeutics
• Gilead Sciences
• Imugene
• Janssen Biotech
• Miltenyi Biomedicine
• Novartis AG
• SOTIO

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN02102025004107003653ID1110140814